Steminent Biotherapeutics Inc. (7729.TWO)
Taipei Exchange · TWD · Healthcare · Biotechnology
NT$173.50 (-3.61%) as of
Key statistics
- Market cap
- 14.00B
- EPS (TTM)
- -3.10
- Dividend yield
- 0.00%
- 52-week range
- 37.85 – 240.00
- Beta
- -0.40
- Profit margin
- 0.00%
- Volume
- 424.34k
About Steminent Biotherapeutics Inc.
Steminent Biotherapeutics Inc. operates as a biopharmaceutical company in Taiwan and the United States. It provides Stemchymal, a cell therapy product for the treatment of neurodegenerative diseases, including spinocerebellar ataxia and huntington's disease; tissue regeneration, such as osteoarthritis; and acute syndromes consisting acute respiratory distress syndrome, liver failure, and ischemic stoke. The company was founded in 2009 and is based in Taipei, Taiwan.
- Sector
- Healthcare
- Industry
- Biotechnology
- Headquarters
- Taipei, Taiwan
Financial statements (income statement, balance sheet, cash flow) and an interactive price chart are available on this page with JavaScript enabled.